"Empagliflozin significantly reduced CI-AKI incidence in PCI patients by enhancing renal function markers, including eGFR and ...

The study was based on 32,819 empagliflozin users and 17,464 dapagliflozin users with type 2 diabetes from the Danish national population. The groups were weighted according to age, sex, diabetes ...

“Our data suggest SGLT2 inhibition as a safe strategy to prevent kidney stone recurrence in patients with kidney stones ,” Dr Fuster’s team concluded. Other study findings indicate the empagliflozin ...

The risk for nonproliferative diabetic retinopathy progression was similar for empagliflozin vs DPP4i therapy. (HealthDay News) — Empagliflozin initiation is not associated with incident ...

Empagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i) primarily developed for glucose control, has shown benefits for cardiovascular and renal outcomes in past clinical trials.

Jardiance is also authorised to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. According to the FDA, heart disease impacts more than ...

First-line empagliflozin, taken once daily for 3 months, leads to a significant reduction in weight, body mass index (BMI), and waist circumference in patients with prediabetes and diabetes.

Disclaimer: AlphaGalileo is not responsible for the accuracy of news releases posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.